Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm expects the life science tools and diagnostics group to be down today and sentiment to shift more negative following Friday’s news around the Trump Administration’s implementation of a 15% cap for National Institutes of Health reimbursement of “indirect costs” on the grants it awards universities. The news likely elevates concern on names like Bruker (BRKR), genomics Illumina (ILMN), 10x Genomics (TXG), and PacBio (PACB) and Thermo Fisher (TMO), Avantor (AVTR), Agilent (A), and Waters (WAT) to a lesser extent, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target lowered to $76 from $80 at BofA
- U.S. places new export controls on biotech equipment, Reuters reports
- Bruker Shares Limited Information Under SEC Regulations
- Bruker sees Q4 revenue $970M-$980M, consensus $962.89M
- Bruker ‘respectfully disagrees’ with District Court, to seek stay of injunction